Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

Brincidofovir · Tembexa, CMX-001

Small molecule · Inhibitor of orthopoxvirus DNA polymerase · developed by Emergent Biodefense

Approved FDA, Jun 2021

EBS Developer

1 Registered trials

What is Brincidofovir?

Brincidofovir is a nucleotide analog DNA polymerase inhibitor active against orthopoxviruses.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as: Tembexa, CMX-001
Drug type: Small molecule
Targets: orthopoxvirus DNA polymerase
Mechanism: Inhibitor of orthopoxvirus DNA polymerase
Therapy area: Infectious disease
Developer: Emergent Biodefense (EBS)
FDA status: Approved as Tembexa (June 4, 2021), NDA214460 · FDA label
UNII: 6794O900AX

✅ FDA-approved uses

Human smallpox disease

From the indications section of the FDA label (version of Jul 23, 2025). Read the full label for the exact wording, limitations and safety information.

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT05935917	Phase 1	Smallpox	Completed	EBS

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Smallpox

More from Emergent Biodefense

AIGIV FDA approved Bacillus anthracis strain V770-NP1-R antigens FDA approved smallpox vaccine live, New York City Board of Health vaccinia strain FDA approved Vaccinia Immune Globulin FDA approved Ad4-EnvC150 Phase 1 Ad4-H5-Vtn Phase 1 Ad4-mgag Phase 1 Ad4-PA-1 Phase 1 Ad4-PA-GPI-1 Phase 1 AIDSVAX B/E Phase 1 AV7909 Phase 3 Botulinum Antitoxin Heptavalent Phase 1

Sources

Updated Oct 3, 2026. Something wrong or missing? Report it on the EBS page.

Follow EBS, the company behind Brincidofovir

See EBS's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

EBS catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z